Comparing Two Anti-CD7 Immunotoxins for Treating Leukaemia
Author Information
Author(s): DJ Flavell, DA Boehm, A Noss, SU Flavell
Primary Institution: The Simon Flavell Leukaemia Research Laboratory, University Department of Pathology, Southampton General Hospital
Hypothesis
Do immunotoxins with two toxin molecules per antibody perform better than those with one in treating leukaemia?
Conclusion
The 2-mer immunotoxin was more effective in vitro but did not show a significant therapeutic advantage in vivo compared to the 1-mer immunotoxin.
Supporting Evidence
- The 2-mer immunotoxin was 5.6 times more effective than the 1-mer in inhibiting protein synthesis in vitro.
- Both immunotoxins showed similar therapeutic outcomes in SCID mice despite the 2-mer's higher in vitro potency.
- Log-rank analysis indicated no significant difference in survival between the two treatment groups.
Takeaway
Researchers tested two types of cancer treatments that deliver toxins to leukaemia cells. One type had two toxins and worked better in the lab, but both types worked similarly in mice.
Methodology
The study involved in vitro tests on HSB-2 leukaemia cells and in vivo tests on SCID mice injected with these cells.
Limitations
The study's findings may not fully translate to human treatments due to differences in mouse models.
Participant Demographics
SCID mice of both sexes, aged 6-10 weeks.
Statistical Information
P-Value
0.6306
Statistical Significance
p=0.6306
Want to read the original?
Access the complete publication on the publisher's website